Novavax, Inc. (BMV:NVAX)

Mexico flag Mexico · Delayed Price · Currency is MXN
126.00
-6.00 (-4.55%)
At close: Jul 31, 2025, 2:00 PM CST
-4.55%
Market Cap20.25B
Revenue (ttm)25.65B
Net Income (ttm)9.78B
Shares Outn/a
EPS (ttm)60.79
PE Ratio2.07
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume513
Average Volume1,876
Open126.50
Previous Close132.00
Day's Range125.50 - 126.99
52-Week Range106.50 - 294.00
Betan/a
RSI41.28
Earnings DateAug 8, 2025

About Chimerix

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1987
Employees 952
Stock Exchange Mexican Stock Exchange
Ticker Symbol NVAX
Full Company Profile

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial Statements

News

There is no news available yet.